Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | PIM1 | P11309 | 7/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 6/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 5/20 | 0.39 |
| ▸ | IGF1R | P08069 | 3/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6449455 | 1.00 | RXRA (0.44) | RXRAGSK3BPIM1PIM2PDE4B | |
| SCHEMBL6450655 | 0.92 | MYC (0.44) | RXRAGSK3BPIM1PIM2PDE4B | |
| SCHEMBL6450651 | 0.92 | MYC (0.44) | RXRAGSK3BPIM1PIM2PDE4B | |
| SCHEMBL6448365 | 0.87 | IGF1R (0.47) | RXRAPIM1PIM2PDE4BPIM3 | |
| SCHEMBL6448359 | 0.87 | IGF1R (0.47) | RXRAPIM1PIM2PDE4BPIM3 | |
| SCHEMBL6450607 | 0.86 | RXRA (0.48) | RXRAPIM1PIM2PDE4BPIM3 | |
| SCHEMBL6450610 | 0.86 | RXRA (0.48) | RXRAPIM1PIM2PDE4BPIM3 | |
| SCHEMBL6449507 | 0.85 | IGF1R (0.54) | RXRAPIM1PIM2PDE4BPIM3 | |
| SCHEMBL6449502 | 0.85 | IGF1R (0.54) | RXRAPIM1PIM2PDE4BPIM3 | |
| SCHEMBL6450617 | 0.84 | RXRA (0.62) | RXRAPIM1PIM2PDE4BPIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038098-A1 | Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases | INCYTE CORPORATION | 2005-02-17 | — | — | US | claimed |
| US-20050038098-A1 | Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases | INCYTE CORPORATION | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038098-A1 | Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases | HSD17B10, IDH2, INSR | RXRA 1054/4885GSK3B 2758/4885PIM1 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.